Tombesi Paolo

EVP & Chief Financial Officer at Turning Point Therapeutics, Inc.; Chief Financial Officer at Epizyme, Inc.

Sold, on record
$148k
Dollars the filings state
Form 4 sales
4
Latest Jul 27, 2022
Form 144 notices
0
Proposed sales
Companies
2
Filed as an executive or holder

Companies

Sales by reason

0
Routine
0
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, last 12 months.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. 1 Form 4 sale Epizyme, Inc.Plan not stated
    Mar 25, 2020 2020

    Sold 1,243 shares at $15.28 ($19k)

    Tombesi Paolo, Chief Financial Officer

    Sold 7.5% of holdings ($255k position)15,437 shares leftFirst sale on recordFiling

  2. 2 Form 4 sale Epizyme, Inc.Plan not stated
    Jun 26, 2020 +93 days

    Sold 1,805 shares at $16.15 ($29k)

    Tombesi Paolo, Chief Financial Officer

    Sold 7.6% of holdings ($384k position)21,942 shares leftFiling

  3. 3 Form 4 sale Epizyme, Inc.Plan not stated
    Feb 4, 2021 +223 days

    Sold 1,021 shares at $11.21 ($11k)

    Tombesi Paolo, Chief Financial Officer

    Sold 1.9% of holdings ($611k position)53,465 shares leftFiling

  4. 4 Form 4 sale Turning Point Therapeutics, Inc.Plan not stated
    Jul 27, 2022 +538 days

    Sold 1,183 shares at $74.94 ($89k)

    Tombesi Paolo, EVP & Chief Financial Officer

    Sold 4% of holdings ($2.2M position)28,700 shares leftFirst sale on recordFiling

Every transaction

Loading transactions…

Sales and notices (4)

Form 144 notices and Form 4 sales by Tombesi Paolo
Source
Jul 27, 2022Jul 29, 2022Turning Point Therapeutics, Inc.EVP & Chief Financial OfficerForm 4 sale1,183$89k4.0%Plan not statedSEC
Feb 4, 2021Feb 5, 2021Epizyme, Inc.Chief Financial OfficerForm 4 sale1,021$11k1.9%Plan not statedSEC
Jun 26, 2020Jun 30, 2020Epizyme, Inc.Chief Financial OfficerForm 4 sale1,805$29k7.6%Plan not statedSEC
Mar 25, 2020Mar 26, 2020Epizyme, Inc.Chief Financial OfficerForm 4 sale1,243$19k7.5%Plan not statedSEC